In a groundbreaking new study published in Pediatric Research, researchers have unveiled promising evidence that sulodexide, a well-established antithrombotic agent, may significantly mitigate lung injury caused by sepsis in neonatal rats. This compelling discovery centers on the modulation of the tumor necrosis factor-alpha (TNF-α) pathway, a pivotal mediator in inflammatory processes. The implications for neonatal care and the broader understanding of sepsis-induced pulmonary complications are profound, heralding a potential shift in therapeutic strategies for one of the most vulnerable patient populations.

Sepsis remains one of the leading causes of morbidity and mortality in neonates worldwide, often precipitating acute lung injury (ALI) through complex inflammatory cascades. The pathophysiology of sepsis-induced lung injury involves an acute and dysregulated immune response, which leads to alveolar damage, vascular permeability, and eventual respiratory failure. Central to this inflammatory milieu is TNF-α, a cytokine extensively studied for its role in promoting inflammation and tissue damage during septic events. Efforts to modulate TNF-α signaling have been ongoing, yet effective and safe therapeutic interventions tailored for neonates have remained elusive until now.

The research team, led by Xie, Song, and Deng, employed a meticulously controlled experimental model utilizing neonatal rats subjected to sepsis induction. They administered sulodexide and monitored a battery of pulmonary function parameters, histological markers, and biochemical assays to assess lung injury and inflammation. Their findings were striking: sulodexide treatment markedly attenuated the severity of lung injury, as evidenced by reduced alveolar damage, diminished inflammatory cell infiltration, and lower levels of TNF-α expression in pulmonary tissues. These outcomes collectively suggest that sulodexide fulfills a dual role, acting both as an anticoagulant and an anti-inflammatory agent in the setting of neonatal sepsis.

At a mechanistic level, the study delves deep into the signaling cascades influenced by sulodexide administration. TNF-α, which drives the recruitment and activation of neutrophils and macrophages, appears to be directly modulated by sulodexide, which subsequently decreases downstream inflammatory mediators such as interleukins and chemokines. This modulation effectively dampens the cytokine storm known to exacerbate tissue injury in septic lungs. The research also highlights sulodexide’s ability to preserve endothelial integrity, preventing the leakage of plasma components into alveolar spaces—a hallmark of acute lung injury.

What makes this study particularly compelling is its relevance to the neonatal immune system, which differs significantly from adults in both its composition and responsiveness. Neonatal immunity is characterized by a heightened vulnerability to both infectious insults and inflammatory injury, necessitating cautious but innovative therapeutic approaches. Sulodexide’s profile, characterized by a relatively favorable safety margin due to its longstanding clinical use in vascular disorders, positions it as an attractive candidate for repurposing in neonatal sepsis management.

Furthermore, the study’s rigorous approach provides a robust framework for future translational research. By integrating histopathological examination with molecular assays, it paints a comprehensive picture of how sulodexide’s anti-inflammatory effects unfold at the cellular level. Notably, the attenuation of TNF-α signaling reduces the expression of adhesion molecules, potentially limiting the recruitment of leukocytes that perpetuate lung damage. These insights deepen our understanding of the critical checkpoints in sepsis-induced lung injury and highlight novel targets for intervention.

The implications of these findings extend beyond the confines of neonatal care. Sepsis-induced lung injury remains a challenging clinical entity in adults as well, and the possibility of sulodexide serving as a multi-faceted therapeutic agent sparks broader interest. Given its existing approval and well-known pharmacodynamics, sulodexide could enter clinical trials relatively swiftly, expediting the bench-to-bedside transition that so often hampers the advent of new treatments.

Critically, the research acknowledges the complexity of sepsis as a systemic syndrome and the myriad factors influencing its progression. While the TNF-α pathway is a major driver of pathogenesis, the multifactorial nature of sepsis-induced organ injury necessitates a combinatorial therapeutic perspective. Thus, sulodexide might be optimally used in conjunction with other interventions, such as antibiotics, supportive respiratory therapies, or immunomodulators, to achieve maximal benefit.

The study also raises important questions regarding dosing, timing, and long-term safety of sulodexide in neonatal subjects. Future investigations must clarify these parameters to ensure that translational application does not compromise the delicate balance of neonatal physiology. Moreover, an evaluation of sulodexide’s effect on systemic coagulation in septic neonates will be crucial, as the risk of bleeding remains a significant clinical concern in this population.

Beyond therapeutic considerations, this research enriches the scientific community’s understanding of neonatal sepsis pathogenesis. The elucidation of how sulodexide interrupts the TNF-α-driven inflammatory cycle offers valuable insights into the molecular choreography underpinning lung injury. It underscores the potential for revisiting established drugs within new pathological contexts, a strategy that accelerates innovation while leveraging existing safety data.

As the medical community grapples with rising rates of antimicrobial resistance and the persistent challenge of sepsis management, findings such as those presented by Xie et al. highlight the importance of targeting host responses rather than pathogens alone. Modifying the inflammatory environment to prevent tissue injury emerges as a promising avenue to improve outcomes, especially in neonates where pathogen clearance strategies must be delicately balanced.

The prospect of sulodexide as a therapeutic agent in neonatal sepsis-induced lung injury introduces a beacon of hope. Its dual anticoagulant and anti-inflammatory properties, combined with its modulatory effect on crucial cytokine pathways, position it within an elite cadre of drugs with the potential to transform neonatal intensive care practices. With further research and clinical validation, sulodexide could revolutionize the management of a condition long viewed as intractable.

This study is a testament to the power of integrative biomedical research bridging pharmacology, neonatology, and immunology. It exemplifies how deep mechanistic insights can drive the repurposing of old drugs, offering new life-saving therapies for vulnerable populations. As such, it invites a reexamination of both scientific dogma and clinical praxis surrounding neonatal sepsis.

The potential public health impact of such interventions cannot be overstated. Improvements in neonatal survival translate to reduced healthcare burdens and better quality of life for countless families globally. Recognizing and harnessing the molecular underpinnings of diseases like sepsis-induced lung injury is imperative for ushering in a new era of personalized and precision medicine.

In summary, the study convincingly demonstrates that sulodexide attenuates sepsis-induced lung injury in neonatal rats primarily via modulation of the TNF-α signaling pathway. This revelation offers a novel therapeutic avenue that warrants expedited clinical exploration. It stands as a beacon in neonatal medicine, promising enhanced outcomes through targeted, mechanism-based intervention.

Subject of Research: Sulodexide’s therapeutic effects on sepsis-induced lung injury in neonatal rats, focusing on the TNF-α inflammatory pathway.

Article Title: Sulodexide attenuates sepsis-induced lung injury in neonatal rats via TNF-α pathway.

Article References:
Xie, L., Song, M., Deng, Z. et al. Sulodexide attenuates sepsis-induced lung injury in neonatal rats via TNF-α pathway. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05067-4

Image Credits: AI Generated

DOI: 02 June 2026

A pioneering research initiative led by the University of Waterloo has unveiled an innovative monitoring system poised to revolutionize the management of brain injuries in intensive care settings. This avant-garde platform is designed to facilitate the early detection of infections, a critical advancement that promises to save countless lives and substantially reduce health-care expenditure associated with brain trauma cases. By enabling continuous and near real-time monitoring of critical biomarkers, this technology marks a significant leap in neurocritical care.

Traditional monitoring of patients suffering from traumatic brain injuries (TBIs) and related neurological conditions such as hydrocephalus and brain hemorrhage often involves the placement of drainage systems to remove excess cerebrospinal fluid (CSF). Annually, approximately 25,000 patients in the United States alone require such interventions. A substantial subset of these cases, up to 20%, experience infections that exacerbate patient outcomes, prolong hospital stays, and result in severe complications including meningitis, neural degradation, permanent disabilities, and, in some cases, fatality. The challenge faced by clinicians has been the labor-intensive and infrequent sampling methods currently employed for infection detection.

Existing protocols rely primarily on intermittent sampling of cerebrospinal fluid, which is then sent to laboratory facilities for microbial and chemical analysis. This process inherently limits testing frequency to once every 24 to 48 hours, significantly delaying critical interventions. Addressing these constraints, the international consortium of researchers embarked on designing a system capable of continuous surveillance, providing granular data on the biochemical milieu within drainage lines without the need for repetitive invasive sampling.

Enter NeuroSense – a sophisticated monitoring device that integrates seamlessly into existing drainage infrastructure. Utilizing electrochemical sensor technology, NeuroSense monitors pivotal biomarkers such as glucose, lactate, and pH levels, all of which serve as early indicators of infection and physiological anomalies within the CSF. The system simultaneously tracks flow rate, an often overlooked but vitally important parameter, as deviations can signal malfunction or obstructions in drainage systems, further compromising patient health.

The compact design of NeuroSense, comparable in size to a modern smartphone, incorporates a 3D-printed housing that accommodates four highly sensitive sensors. These sensors interface with an electrochemical analyzer capable of processing signal transduction from biochemical changes rapidly and accurately. The results are displayed on an intuitive bedside monitor, granting physicians and nurses immediate access to actionable data and enabling rapid clinical decision-making.

Such real-time monitoring represents a paradigm shift in neurocritical care. The instantaneous feedback loop provided by NeuroSense ensures that emerging infections or drain anomalies are identified promptly, circumventing the historical delays intrinsic to laboratory testing. This technological breakthrough allows health-care providers to initiate targeted treatments sooner, thereby reducing complications, hospital length of stay, and overall health-care costs.

The development of NeuroSense was spearheaded by a multidisciplinary team featuring expertise from electrical and computer engineering, biomedical science, and clinical neurology. Dr. Mahla Poudineh, a professor at Waterloo and the Canada Research Chair in Health Monitoring BioNano Devices, highlighted the transformative potential of this system. Alongside PhD candidate Fatemeh Keyvani, who led much of the hands-on research development, the team validated the device’s performance through comparative laboratory experiments and preliminary clinical trials within intensive care units.

Initial validation involved rigorous benchmarking against standard cerebrospinal fluid testing methodologies. The system’s ability to detect shifts in glucose and lactate concentrations, both metabolic indicators sensitive to infection-related changes, demonstrated remarkable correlation with traditional diagnostic data. These findings were corroborated by pilot testing within hospital ICUs, where NeuroSense contributed valuable continuous data streams previously unattainable by conventional methods.

Looking forward, researchers aim to enhance NeuroSense’s clinical utility by incorporating automated alert mechanisms that can notify care teams instantly upon detection of critical deviations. This feature would not only optimize response times but also alleviate continuous manual monitoring burdens on medical staff. Furthermore, comprehensive multicenter clinical trials are planned to provide robust statistical validation and facilitate regulatory approval, propelling the device toward widespread commercial availability.

Critical collaboration underpinned this success, with researchers from renowned institutions including University Medicine Rostock in Germany, Massachusetts Institute of Technology, and Harvard Medical School contributing essential expertise. This international cooperation synergized engineering innovation with clinical insights, underscoring the multidisciplinary nature of modern biomedical engineering challenges.

The scientific community has recently acknowledged this work through publication in the prestigious journal Science Translational Medicine. The article, titled “A platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical care,” delineates the comprehensive design, testing, and clinical implications of the NeuroSense platform. It stands as a testament to the growing intersection of engineering and medicine, promising not only to enhance clinical outcomes but also to set new standards for patient monitoring technologies in critical care environments.

In summary, NeuroSense exemplifies the potential of advanced bioengineering to address longstanding clinical challenges by delivering a practical, efficient, and precise monitoring solution. It offers a beacon of hope for patients afflicted with traumatic brain injuries and related neurological conditions, where timely detection and management of complications such as infections can markedly influence recovery trajectories. As development proceeds, this technology is expected to become an indispensable component of neurocritical care protocols worldwide.

Subject of Research: Continuous Monitoring and Early Detection of Infections in Traumatic Brain Injury Patients

Article Title: A platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical care

News Publication Date: Not provided

Web References: https://www.science.org/doi/10.1126/scitranslmed.aeb1381

References: Science Translational Medicine (journal publication)

Image Credits: Not provided

Keywords

Brain injuries, Traumatic brain injury, Health care, Biomedical engineering, Neurocritical care, Cerebrospinal fluid monitoring, Infection detection, Electrochemical sensors, Hospital intensive care, Medical devices

In recent years, the medical community has begun to critically reassess the longstanding reliance on Body Mass Index (BMI) as the primary tool for evaluating obesity and its associated health risks. Despite its widespread use as a simple and accessible measure, BMI fails to distinguish between muscle mass, bone density, and actual body fat. This inability to account for fat distribution and composition means that a substantial portion of individuals with potentially serious obesity-related complications may slip through the conventional screening process undetected. Now, groundbreaking research from Keck Medicine of USC challenges the adequacy of BMI by introducing clinical obesity as a more precise and meaningful metric for identifying at-risk individuals.

Traditional calculations of BMI classify individuals based solely on the ratio of their weight to height, typically categorizing those with a BMI under 18.5 as underweight, between 18.5 and 25 as normal or healthy weight, between 25 and 29.9 as overweight, and 30 or above as obese. However, this methodology overlooks a crucial factor integral to metabolic health: the location and nature of adipose tissue. BMI’s inability to differentiate between lean muscle and fat means that muscular individuals might be labeled obese, whereas normal-weight individuals with excessive visceral fat remain unrecognized as having clinically significant obesity.

The concept of clinical obesity, developed in 2025 by the Lancet Diabetes and Endocrinology Commission, directly addresses the shortcomings of BMI by focusing on visceral fat accumulation, particularly in the abdominal region. Unlike subcutaneous fat, which lies just beneath the skin, visceral adipose tissue infiltrates deep within the abdominal cavity, surrounding vital organs and releasing inflammatory mediators that contribute to metabolic dysfunction and chronic disease. This inflammation plays a pivotal role in the pathogenesis of insulin resistance, cardiovascular disease, and other obesity-related morbidities.

Measurement of clinical obesity involves three key anthropometric parameters: waist circumference, waist-to-hip ratio, and waist-to-height ratio. These metrics provide a more nuanced assessment of fat distribution, enabling clinicians to detect dangerous levels of abdominal adiposity. If an individual exceeds established thresholds in at least two of these measurements and exhibits health impairments commonly linked to excess visceral fat—such as hypertension, diabetes, or joint pain—they are classified as clinically obese, regardless of their BMI category.

A new study led by hepatologist and liver transplant specialist Dr. Brian P. Lee, MD, MAS, and published in the Annals of Internal Medicine, systematically analyzed data from 5,600 adults aged approximately 49 years in the National Health and Nutrition Examination Survey (NHANES). Their findings unequivocally highlight the limitations of BMI: an estimated 26% of individuals categorized as having a normal BMI by conventional standards are, in fact, clinically obese. Furthermore, half of those classified as overweight by BMI also meet criteria for clinical obesity, underscoring the vast underdiagnosis potential inherent in BMI screening.

This underrecognition poses serious implications for public health and clinical practice. Presently, many treatment protocols, including pharmacologic and surgical options for obesity, are contingent upon BMI thresholds, inadvertently excluding millions who suffer the metabolic consequences of fat deposition despite “normal” weight status. Dr. Lee emphasizes that this gap means patients with normal or slightly elevated BMI values may miss timely interventions that could prevent progression to severe disease states.

The distinguishing capacity of clinical obesity to identify high-risk phenotypes that BMI overlooks is particularly vital given the wide spectrum of obesity-related diseases. Excess visceral fat is implicated in the etiology of type 2 diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and certain malignancies. Moreover, chronic inflammation fueled by adipose tissue contributes to early vascular aging and organ dysfunction, making early detection a cornerstone for effective disease management.

Importantly, clinical obesity is not an inescapable destiny; it is a modifiable condition. Evidence-based interventions spanning lifestyle modifications, tailored pharmacotherapy, and in selected cases, bariatric surgery, have demonstrated effectiveness in reducing visceral fat and improving metabolic outcomes. However, success hinges on accurate diagnosis and stratification, areas where clinical obesity proves superior to BMI.

The compelling research results advocate for a paradigm shift in obesity screening and diagnosis. Dr. Lee envisions the integration of clinical obesity metrics into routine medical practice, augmenting current approaches. Doing so would refine risk assessments, enable personalized treatment pathways, and potentially reduce the incidence of obesity-related complications that represent a substantial burden on healthcare systems worldwide.

Furthermore, these insights challenge public perceptions of obesity, moving beyond the simplistic reliance on weight charts toward a more sophisticated understanding of metabolic health. The emphasis on adiposity rather than body weight alone could decrease stigma by reframing obesity as a complex biological condition rather than merely a cosmetic issue.

This evolving understanding also holds promise for advancing research into obesity pathophysiology. By employing clinical obesity criteria, studies can more accurately stratify participants, enhancing the validity of findings regarding interventions and outcomes. Such precision could drive innovation in therapeutics targeting visceral fat reduction and inflammation modulation.

In summary, the transition from BMI to clinical obesity assessment marks a critical evolution in the medical evaluation of obesity. The nuanced approach recognizes the heterogeneous nature of obesity and its metabolic consequences, advocating for improved diagnostic accuracy to ultimately enhance patient care and public health outcomes. Widespread adoption of this approach could redefine how clinicians worldwide identify and manage obesity, offering new hope for millions at risk of preventable disease.

Subject of Research: Evaluation of obesity measurement methods comparing Body Mass Index (BMI) and clinical obesity criteria.

Article Title: Limitations of BMI in Obesity Diagnosis: Clinical Obesity as a Superior Metric for Identifying At-Risk Individuals

News Publication Date: 2024

Web References:

• Keck Medicine of USC Liver Health Center
• Study in Annals of Internal Medicine
• Clinical Obesity Measurement Guidelines

Image Credits: PHOTO COURTESY OF BRIAN P. LEE, MD, MAS

Keywords: Body Mass Index, Clinical Obesity, Visceral Fat, Adipose Tissue, Obesity-Related Health Risks, Metabolic Syndrome, Waist Circumference, Waist-to-Hip Ratio, Waist-to-Height Ratio, Inflammation, Hepatology, Obesity Diagnosis

For years, anti-vaccine Health Secretary Robert F. Kennedy Jr. and his zealous followers have downplayed measles as "just a rash" and falsely claimed that "Measles outbreaks have been fabricated to create fear."

In 2021, when Kennedy wrote those words, the US recorded just 49 measles cases. Yearly case counts have generally been low since 2000, when the US declared measles eliminated thanks to a decades-long vaccination campaign. But with the rise of Kennedy and his ilk in the past few decades, that public health triumph is being undone. Vaccination rates have slipped, and large, multistate outbreaks of vaccine-preventable diseases have inevitably come roaring back. Now it's becoming painfully clear once again how wrong Kennedy and his cohorts are about infectious diseases and vaccines.

In a study published yesterday in the Morbidity and Mortality Weekly Report, state and federal researchers provided a detailed postmortem of last year's massive multi-state measles outbreak that mushroomed out of West Texas. The data reveals a disease that's far from just a rash, with about 20 percent of people—mostly younger children—being hospitalized.

Read full article

Comments

For years, anti-vaccine Health Secretary Robert F. Kennedy Jr. and his zealous followers have downplayed measles as "just a rash" and falsely claimed that "Measles outbreaks have been fabricated to create fear."

In 2021, when Kennedy wrote those words, the US recorded just 49 measles cases. Yearly case counts have generally been low since 2000, when the US declared measles eliminated thanks to a decades-long vaccination campaign. But with the rise of Kennedy and his ilk in the past few decades, that public health triumph is being undone. Vaccination rates have slipped, and large, multistate outbreaks of vaccine-preventable diseases have inevitably come roaring back. Now it's becoming painfully clear once again how wrong Kennedy and his cohorts are about infectious diseases and vaccines.

In a study published yesterday in the Morbidity and Mortality Weekly Report, state and federal researchers provided a detailed postmortem of last year's massive multi-state measles outbreak that mushroomed out of West Texas. The data reveals a disease that's far from just a rash, with about 20 percent of people—mostly younger children—being hospitalized.

Read full article

Comments